Johnson & Johnson (JNJ) Financial Analysis & Valuation | Quarter Chart
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the... more
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and se... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $621.22B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Joaquin Duato |
| IPO Date | 1962-01-02 | CAGR | 6.94% |
| Employees | 141,700 | Website | www.jnj.com |
| Div. Yield | 1.92% | Payout Ratio | 78% |
| Buy Back Yield | 1.21% | Total Yield | 3.13% |
JNJ chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $662.21B | P/E | 24.02 | Forward P/E | 22.32 | PEG | -0.41 |
| P/S | 6.67 | P/B | 7.93 | P/CF | 28.41 | P/FCF | 35.43 |
| Sales | $99.33B | Sales 1Y | 7.8% | Sales 3Y | 13.56% | Sales 5Y | 8.63% |
| EPS | $10.73 | EPS 1Y | -36.33% | EPS 3Y | -51.03% | EPS 5Y | -1.41% |
| Sales QoQ | 0.35% | EPS QoQ | -96.22% | Sales QoQ Avg | 1.47% | EPS QoQ Avg | -22.3% |
| Gross Margin | 68.81% | Operating Margin | 25.7% | Profit Margin | 16.2% | ROCE | 17.46% |
| ROA | 8% | ROE | 20% | Altman Z Score | 5.3 | Piotroski Score | 6 |
| Current Ratio | 1.09 | Quick Ratio | 0.81 | Cash Ratio | 0.37 | Op. CF Ratio | 0.09 |
| Debt/Equity | 0.58 | Debt/Assets | 0.24 | Lt Debt/Equity | 0.44 | Lt Debt/Cap. | 0.31 |
| Intrst Cov. | 31.99 | Inventory Turnover | 2.05 | Asset Turnover | 0.49 | Receivables Turnover | 5.22 |
| Enterprise Value | $662.21B | P/E Ratio | 24.02 |
| Forward P/E | 22.32 | PEG Ratio | -0.41 |
| P/S Ratio | 6.67 | P/B Ratio | 7.93 |
| P/CF Ratio | 28.41 | P/FCF Ratio | 35.43 |
| EPS | $10.73 | EPS Growth 1Y | -36.33% |
| EPS Growth 3Y | -51.03% | EPS Growth 5Y | -1.41% |
| Revenue Growth 1Y | 7.8% | Gross Margin | 68.81% |
| Operating Margin | 25.7% | Profit Margin | 16.2% |
| ROE | 20% | ROA | 8% |
| ROCE | 17.46% | Current Ratio | 1.09 |
| Quick Ratio | 0.81 | Cash Ratio | 0.37 |
| Debt/Equity | 0.58 | Interest Coverage | 31.99 |
| Altman Z Score | 5.3 | Piotroski Score | 6 |
Johnson & Johnson (JNJ) valuation & financials
Johnson & Johnson (JNJ) has a market capitalization of $621.22B and trades at a price-to-earnings ratio of 24.0. It operates in the Healthcare sector (Drug Manufacturers - General).
Johnson & Johnson's revenue grew +7.8% over the last year.
Johnson & Johnson's next earnings report is scheduled for January 20, 2027 before market open (provider scheduled date); analysts estimate EPS of $2.93. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW) · Novartis (NVS)